SUMITOMO CHEMICAL COMPANY,LIMITED Q2 FY2026 earnings call

• Financial Performance: The company reported record-high first-half results with core operating income of JPY 144.5 billion and net income of JPY 82.9 billion, both exceeding forecasts.
• Balance Sheet Strength: The D/E ratio improved significantly to 0.73x and equity ratio to 32.1%, largely due to Sumitomo Pharma’s capital increase and retained earnings.
• Segment Dynamics:
  • Agro & Life: Feed additive margins improved, but overseas crop protection recovery is delayed due to credit uncertainties in Latin America and El Niño impacts in India.
  • ICT & Mobility: Semiconductor demand remains solid, particularly for front-end resistors and chemicals, offsetting sluggish mobile device markets.
  • Essential & Green: Petro Rabigh benefited from resolving prior maintenance issues, while inventory gains in Japan/Singapore were substantial.
  • Sumitomo Pharma: Strong growth in key drugs Orgovyx and Gemtesa, though one-time gains from Asian business sales are no longer present.
• Operational Risks: Naphtha prices remain high (JPY 107,500/kiloliter), impacting petrochemical margins. Middle East geopolitical tensions continue to create uncertainty for operations and supply chains.

Agro & Life Solutions: Core operating income was JPY 20.8 billion, up JPY 9.6 billion year-on-year, driven by improved margins in feed additives despite delayed recovery in overseas crop protection sales. ICT & Mobility Solutions: Core operating income was JPY 31.9 billion, down JPY 1.2 billion year-on-year, negatively impacted by lower display-related shipments and prices, but supported by strong semiconductor processing material demand and super engineering plastics. Advanced Medical Solutions: Core operating income was a loss of JPY 3.7 billion, down JPY 2.3 billion year-on-year, due to unfavorable sales mix changes and margin declines at affiliated companies. Essential & Green Materials: Core operating income was JPY 62.1 billion, up JPY 80.7 billion year-on-year, significantly boosted by inventory valuation gains and improved Petro Rabigh results. Sumitomo Pharma: Core operating income was JPY 43.6 billion, down JPY 53.8 billion year-on-year, primarily due to the absence of prior-year gains from business sales, though organic shipments grew.

• FY 2026 Core Operating Income: Revised upward by JPY 55 billion to JPY 270 billion (from previous JPY 250 billion forecast).
• FY 2026 Net Income Attributable to Owners: Revised upward by JPY 20 billion to JPY 90 billion (from previous JPY 70 billion forecast).
• Dividend: Year-end dividend revised upward by JPY 1 to JPY 9 per share; full-year annual dividend projected at JPY 17 per share.
• Sales Revenue: Forecast increased by JPY 130 billion to JPY 2.49 trillion.
• Key Assumptions: Exchange rate assumed at JPY 157/USD for the full year; naphtha price assumed at JPY 99,000/kiloliter.

• Geopolitical Instability: Ongoing tensions in the Middle East pose risks to supply chains, operational continuity (e.g., Petro Rabigh), and market stability.
• Market Volatility: Delayed recovery in overseas crop protection markets due to farmer credit issues and weather patterns (El Niño).
• Raw Material Costs: Persistently high naphtha prices squeeze petrochemical margins and require continuous price negotiations with customers.
• Inventory Valuation: Fluctuations in feedstock and product prices lead to significant unrealized gains or losses on inventory, creating visibility challenges for the second half.

Q: Why was Agro & Life Q2 performance below forecast, and what drives the H2 revision?

A: Overseas crop protection recovery is delayed in Latin America due to farmer credit uncertainty and El Niño impacts reducing purchasing. In India, delayed monsoons also hindered sales. However, methionine prices stabilized after initial confusion, allowing for an upward revision in H2 income as supply-demand balances settle and shipments shift forward.

Q: What factors support the upward revision in ICT & Mobility Solutions and Essential & Green Materials?

A: ICT & Mobility benefits from strong semiconductor processing material demand and super engineering plastics shipments, outweighing display sector weakness. Essential & Green saw massive profit increases due to temporary inventory valuation gains from high feedstock prices and improved Petro Rabigh refining margins following resolved maintenance issues.

Q: How should investors interpret the negative 'Others' segment forecast and non-recurring items?

A: Management incorporated approximately JPY 10 billion in risk buffers for the 'Others' segment, primarily reflecting uncertainties surrounding the Middle East situation and potential inventory valuation losses. Non-recurring items are expected to be more prominent in H2 compared to H1, similar to last fiscal year's restructuring expenses, indicating a cautious stance on future volatility.

Q: What is the strategic outlook for dividends given current profitability drivers?

A: While H1 performance was strong, management acknowledges H2 uncertainties and geopolitical risks. The dividend was raised based on a comprehensive view of this year and next year's outlook. They aim to maintain high dividend levels if future prospects brighten but emphasize that the decision reflects a balance between rewarding shareholders and managing risk.